| |
|
Timing of hepatitis C elimination in the United States: Estimating the year each state will achieve the World Health Organization's elimination targets
|
| |
| |
DDW May 2020
Reported by Jules Levin, NATAP
Mark Sulkowski1, Wei-Han Cheng2, Steven Marx2, Yuri Sanchez Gonzalez2, Nancy Reau3
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA; 3Rush University Medical Center, Chicago, IL, USA
Presenter: Nancy Reau
Timing of hepatitis C elimination in the United States: Estimating the year each state will achieve the World Health Organization's elimination targets
DDW May 2020 - Presenter: Nancy Reau
HCV Elimination in Australia vs USA - (05/21/20)
In Australia HCV elimination project is ongoing: routine testing, unrestricted DAA access produced high treatment uptake, costs deals with drug companies, government buy-in
Using the most recent NHANES data, investigators estimated only 55.6% of persons infected with HCV in theUnited States were aware of their HCV infection status.[14]. Awareness of infection status was lower inpersons who were foreign-born and in persons with income below poverty level.[14] These most recentNHANES data do not show a major improvement from a prior analysis of NHANES data (from 2001-2008) that reported 50% of persons infected with HCV were aware of their HCV infection status.[15] Awareness of HCVstatus may be higher among persons enagned in the private health care sector: a study involving personswith access to medical care in four private health care organizations during the years 2006 to 2008, showedan estimated 57% were aware of their HCV infection.[16].
https://www.hepatitisc.uw.edu/pdf/screening-diagnosis/epidemiology-us/core-concept/all
----------------------------------
Timing of hepatitis C elimination in the United States: Estimating the year each state will achieve the World Health Organization's elimination targets
DDW May 2020
Reported by Jules Levin, NATAP
Mark Sulkowski1, Wei-Han Cheng2, Steven Marx2, Yuri Sanchez Gonzalez2, Nancy Reau3
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA; 3Rush University Medical Center, Chicago, IL, USA
Presenter: Nancy Reau
| |
| |
| |
|
|
|
